Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • antineoplastic therapy
Systemic Anticancer Therapy in the Last 30 Days of Life Is Tied to More Acute Care and Less Hospice Use in Older Adults: A SEER–Medicare Analysis
Posted inHematology-Oncology news Oncology

Systemic Anticancer Therapy in the Last 30 Days of Life Is Tied to More Acute Care and Less Hospice Use in Older Adults: A SEER–Medicare Analysis

Posted by MedXY By MedXY 12/12/2025
A SEER–Medicare study of 315,089 older adults found that systemic anticancer therapy within 30 days of death—whether cytotoxic, targeted, immunotherapy, or combinations—was associated with substantially higher acute care use and lower hospice enrollment.
Read More
  • Antipsychotic Exposure in the ICU: A Double-Edged Sword for Catatonia Risk?
  • Strengthening the Safety Net: Insights from the First National Assessment of EMS Pediatric Readiness
  • Bridging the Gap in Emergency Care: The National Assessment of Pediatric Readiness in EMS
  • Breaking the Silos: How the PACE-It Model Improves Outcomes in Multimorbid Patients through Integrated Social and Clinical Care
  • Bridging the Health-Social Gap: The PACE-It Model Shows Promise for Complex Multimorbidity Management
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in